TargetBeta
AGTR1
angiotensin II receptor type 1 · also AT1, AT2R1, AGTR1A, AT2R1A · Angiotensin receptors
5 programs in company-led studies act on AGTR1, from 5 companies: 0 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 1455 running | – | ChEMBL |
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 1324 running | – | ChEMBL |
| sparsentanrule | Travere Therapeutics | phase 4 | 92 running | EDNRA | ChEMBL |
| Losartanrule | Organon | phase 4 | 581 running | – | ChEMBL |
| azilsartan medoxomilrule | Takeda | phase 4 | 251 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Hypertension, 5 programs
- Essential Hypertension, 4 programs
- Proteinuria, 3 programs
- Diabetes Mellitus, Type 2, 2 programs
- Heart Failure, 2 programs
- Diabetic Nephropathies, 1 program
- Glomerulonephritis, IGA, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
- Hypercholesterolemia, 1 program
- Hyperlipidemias, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027Losartan · Organon · phase 4 · NCT07784621
- Mar 2027sparsentan · Travere Therapeutics · phase 4 · NCT07219121
- Apr 2027Telmisartan · Boehringer Ingelheim · phase 4 · NCT07784608
- Dec 2027Valsartan · Novartis · phase 4 · NCT06863987
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.